CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γD T In Vivo Persistency

The MOU signed by CytoMed and Hangzhou CNK Therapeutics Co., Ltd is the first of several collaborative efforts in North Asia.  

 CytoMed Therapeutics Limited a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announces today that it signed a Memorandum of Understanding (MOU) with Hangzhou CNK Therapeutics Co., Ltd (CNK). With this agreement, CytoMed can utilize CNK's PiggyBac technology to permanently graft the Chimeric Antigen Receptor (CAR) gene into its gamma delta (γδ) T cells via a non-viral gene editing method. "We are currently using mRNA technology whereby the CAR gene is transient, and hence, the CAR expression would cease after a period of time, leaving non-CAR γδ T cells in the patient's body," said Dr. Tan Wee Kiat, Chief Operating Officer of CytoMed. "The γδ T cells that remain continue to be cytotoxic with the ability to kill cancer cells. Leveraging CNK's technology, the CAR gene now would be expressed for as long as the γδ T cells are present in the body. This means that the CAR-γδ T cells can now exert a targeted attack for as long as it is present in the patient's body, potentially increasing the efficacy of our CAR γδ T cells in the patient."

CytoMed was initially introduced to this opportunity by Professor Wang Shu, an advisor on the CytoMed Scientific Advisory Committee and co-inventor of the Company's CAR γδ T cell technology. Professor Wang Shu's deep understanding of cell therapy research, specifically CytoMed's technology, made it possible to discern the potential matching synergy between CytoMed and CNK's PiggyBac technologies.

The MOU has a duration of one year, with the option to renew, and is subject to a definitive agreement and customary closing conditions. There remains a potential opportunity for a joint venture to conduct clinical trials in China.

The signing ceremony took place on Tuesday, August 15 at the 17^th Singapore-Zhejiang Economic and Trade Council Meeting. In attendance was Senior Minister of State for National Development and Foreign Affairs Sim Ann and Zhejiang Vice Governor Lu Shan.

"Such strategic partnerships augment CytoMed's technology and bring us one step closer to our goal of advancing affordable, "off-the-shelf" allogeneic cellular immunotherapies for a broad spectrum of cancers," said Peter Choo, Chairman of CytoMed. "We look forward to continuing our growth with new and innovative partnerships." About CytoMed Therapeutics Limited (CytoMed)

Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore's leading research and development agency in the public sector. It is a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating hematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!